Citation | Devasthale, P; Wang, Y; Wang, W; Fevig, J; Feng, J; Wang, A; Harrity, T; Egan, D; Morgan, N; Cap, M; Fura, A; Klei, HE; Kish, K; Weigelt, C; Sun, L; Levesque, P; Moulin, F; Li, YX; Zahler, R; Kirby, MS; Hamann, LG Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem56:7343-57 (2013) [PubMed] Article |
---|
SMILES | CN(C)C(=O)Cn1cc2[nH]c(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2c1=O |(43.67,-17.4,;42.13,-17.41,;41.36,-16.08,;41.37,-18.75,;39.83,-18.76,;42.15,-20.08,;43.69,-20.07,;44.59,-18.81,;46.06,-19.29,;47.39,-18.52,;48.73,-19.28,;50.06,-18.51,;48.73,-20.83,;50.07,-21.6,;51.4,-20.83,;47.4,-21.6,;47.4,-23.14,;46.06,-23.9,;46.06,-25.44,;47.39,-26.22,;47.39,-27.76,;48.73,-25.44,;48.73,-23.91,;50.06,-23.14,;46.07,-20.83,;44.6,-21.32,;44.13,-22.79,)| |